Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers

Abstract

Left ventricular hypertrophy (LVH) refers to a complex rebuilding of the left ventricle that can gradually lead to serious complications—heart failure and life-threatening ventricular arrhythmias. LVH is defined as an increase in the size of the left ventricle (i.e., anatomically), therefore the basic diagnosis detecting the increase in the LV size is the domain of imaging methods such as echocardiography and cardiac magnetic resonance. However, to evaluate the functional status indicating the gradual deterioration of the left ventricular myocardium, additional methods are available approaching the complex process of hypertrophic remodeling. The novel molecular and genetic biomarkers provide insights on the underlying processes, representing a potential basis for targeted therapy. This review summarizes the spectrum of the main biomarkers employed in the LVH valuation.

Untitled

“…Hypertrophy of the heart muscle in hypertension individuals is defined not only by a rise in myocardial mass, but also by fibrous tissue growth and a reduction in intercellular coupling. These changes can result in the development of different arrhythmias [20,21]. The present study revealed a significant prevalence of LVH among patients diagnosed with AF, with a rate of 56%.…”